Cerus Corporation (CERS)
| Market Cap | 1.12B |
| Revenue (ttm) | 107.15M |
| Net Income (ttm) | -62.40M |
| Shares Out | 166.57M |
| EPS (ttm) | -0.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 24 |
| Last Price | $6.72 |
| Previous Close | $6.77 |
| Change ($) | -0.05 |
| Change (%) | -0.74% |
| Day's Open | 6.71 |
| Day's Range | 6.50 - 6.93 |
| Day's Volume | 1,461,151 |
| 52-Week Range | 2.71 - 8.87 |
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today preliminary product revenue for the fourth quarter and full year 2020 and provided 2021 product revenue guida...
Cerus' FDA & CE approved Intercept pathogen reduction platform for platelets and plasma gathering momentum as FDA Guidelines require compliance with new blood safety measures by March 31, 2021...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that its distribution partner, Companhia Energética Integrada (CEI), was awarded a three-year contract with t...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the oral presentation of a clinical study: “Efficacy of COVID-19 Pathogen Inactivated Convalescent Plasma for...
Does Cerus (CERS) have what it takes to be a top stock pick for momentum investors? Let's find out.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryopre...
Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that William ‘Obi' Greenman, Cerus' president and chief executive officer, and Kevin D. Green, Cerus' chief f...
Cerus Corporation (CERS) CEO Obi Greenman on Q3 2020 Results - Earnings Call Transcript
Cerus (CERS) delivered earnings and revenue surprises of 33.33% and 2.20%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2020. Recent developments and highlights include:...
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its third quarter 2020 financial results will be released on Thursday, October 29, 2020, after the close ...
Cerus Inks FDA Contract, And Other News: The Good, Bad And Ugly Of Biopharma
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of ne...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today its lineup of abstract presentations at the AABB 2020 Virtual Annual Meeting, which will take place on October...
The pandemic highlights how far medical science has come. It also highlights how exciting the future is.
Convalescent plasma stocks moved northward following FDA's emergency plasma authorization for COVID-19 treatment. Here're three of them that should be on your watch list -
Health care stocks levered to blood collection and sampling, and plasma therapy biopharma companies are getting a big boost Monday after the FDA issued emergency use authorization for the use ...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that INTERCEPT Blood Systems disposable kit shipments have surpassed 7.5 million treatable platelet and plasma...
Cerus Corporation (CERS) CEO Obi Greenman on Q2 2020 Results - Earnings Call Transcript
Cerus (CERS) delivered earnings and revenue surprises of 10.00% and 0.01%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the second quarter ended June 30, 2020.
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has been awarded a five-year tender by the Hong Kong Red Cross Blood Transfusion Services (BTS) for INTERCE...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today that its second quarter 2020 financial results will be released on Tuesday, August 4, 2020, after the close of...
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) announced today study results demonstrating that the INTERCEPT Blood System inactivates SARS-CoV-2, the causative agent for CO...
Is (CERS) Outperforming Other Medical Stocks This Year?
Cerus CEO on convalescent plasma, blood centers being the pandemic's 'unsung heroes'
Biotech company Cerus CEO Obi Greenman discussed early findings of using plasma to fight Covid-19.
Cerus (CERS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cerus Corporation (CERS) CEO Obi Greenman on Q1 2020 Results - Earnings Call Transcript
Cerus (CERS) delivered earnings and revenue surprises of 0.00% and 5.74%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Cerus Corporation (CERS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
As of late, it has definitely been a great time to be an investor in Cerus Corporation (CERS).
Cerus: Looks Ready To Breakout Following Another Positive Earnings Report
Cerus Corporation (CERS) CEO Obi Greenman on Q4 2019 Results - Earnings Call Transcript
Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.
The newest coronavirus out of China has resulted in a rising interest in biotechs that may be able to produce a vaccine or treatment with a short turnaround.
Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.
While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
Cerus Corporation's (CERS) CEO Obi Greenman on Q3 2019 Results - Earnings Call Transcript
The company recently reported their Q2 earnings revealing increased demand for their INTERCEPT products with a slight beat on revenue and a slight miss on EPS.
Cerus Corporation (CERS) CEO Obi Greenman on Q2 2019 Results - Earnings Call Transcript
Cerus (CERS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerus Corporation (CERS) CEO Obi Greenman on Q1 2019 Results - Earnings Call Transcript
About CERS
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma that is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells... [Read more...]
| Industry Biotechnology | IPO Date Jan 30, 1997 |
| CEO William Greenman | Employees 254 |
| Stock Exchange NASDAQ | Ticker Symbol CERS |
Financial Performance
In 2019, Cerus's revenue was $93.77 million, an increase of 23.30% compared to the previous year's $76.05 million. Losses were -$71.24 million, 23.8% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Cerus stock is "Strong Buy." The 12-month stock price forecast is 9.30, which is an increase of 38.39% from the latest price.